Skip to Main Content

Paper Details

Signature-driven repurposing of Midostaurin for combination with MEK1/2 and KRASG12C inhibitors in lung cancer.
Nat Commun
2
2023
AURKB, KRAS, KRAS-mutated lung cancers, KRASG12C, MEK1/2, MYC, Midostaurin, PKC, anti, cancer, lung cancer, tumor, tyrosine, tyrosine kinase
Author NameAffiliation
Fernando LecandaUniversity of Navarra, Center for Applied Medical Research
Fernando LecandaUniversity of Navarra
Fernando LecandaNavarra Institute for Health Research
Fernando Lecanda
Fernando LecandaUniversity of Navarra, Center for Applied Medical Research
Fernando Lecanda
Fernando LecandaNavarra Institute for Health Research
Fernando LecandaUniversity of Navarra
Davide RuggeroHelen Diller Family Comprehensive Cancer Center, University of California San Francisco
Davide RuggeroUniversity of California San Francisco
Davide RuggeroUniversity of California San Francisco
Purvesh KhatriUniversity of California San Francisco
Purvesh KhatriComplejo Hospitalario de Navarra (CHN), Universidad Publica de Navarra
Purvesh KhatriUniversity of California San Francisco
Purvesh KhatriComplejo Hospitalario de Navarra (CHN), Universidad Publica de Navarra
  • 1 - 15

Datasets

Release 1.2